Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 03 November 2020
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19 15 July 2020
Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges 25 June 2020
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts 22 June 2020
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia 29 April 2020
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program 08 April 2020
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response 24 March 2020
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa 04 March 2020
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters 10 December 2019
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa 20 November 2019
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease 17 October 2019
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence 03 October 2019
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine 06 September 2019
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention 11 July 2019
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio 01 July 2019
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® 07 June 2019
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial 03 June 2019
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment 22 May 2019
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care 14 May 2019
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians 07 May 2019